Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Innate Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Araris Biotech Acquires Innate Pharma Patents For Antibody-Drug Conjugates
Details : Araris biotech expands its ip portfolio with the acquisition of innate pharma’s portfolio of transglutaminase patents for the generation of antibody-drug conjugates.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Innate Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Araris will use its proprietary linker-conjugation platform to generate next-generation novel ADCs against undisclosed targets provided by Taiho.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Innosuisse
Deal Size : $2.8 million
Deal Type : Funding
Details : Araris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates. Araris’ ADC linker technology enables payload attachment to off the shelf antibodies without needing to re-engine...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 05, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Innosuisse
Deal Size : $2.8 million
Deal Type : Funding
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Araris Biotech AG Acquires ARS Pharmaceutical's Nectin-4 Antibody
Details : Araris intends to use the antibody in the development of a differentiated Nectin-4 ADC using its proprietary linker technology to broaden its Antibody-drug Conjugate pipeline.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 17, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Antibody Drug Conjugate
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : Samsung Venture Investment Corporation
Deal Size : Undisclosed
Deal Type : Financing
Araris Biotech AG Announces Strategic Investment with Samsung Ventures
Details : The net proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate candidates using company's proprietary antibody-drug conjugate (ADC)-linker technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 11, 2023
Lead Product(s) : Antibody Drug Conjugate
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : Samsung Venture Investment Corporation
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : ARC-02
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week
Details : ARC-02 demonstrated potent cytotoxicity in three different non-Hodgkin Lymphoma (NHL) cell lines, with similar potency to Polivy® despite ARC-02’s having a lower drug load.
Brand Name : ARC-02
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : ARC-02
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Araris Biotech Closes $24 Million Financing Round
Details : Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical develo...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 04, 2022
Lead Product(s) : ADC-based Therapeutic
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit
Details : The resulting ADC-based Therapeutic have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 21, 2022
Lead Product(s) : ADC-based Therapeutic
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polatuzumab-monomethyl auristatin E
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate contains polatuzumab (non-engineered) as targeting antibody and monomethyl auristatin E as payload highlight late-breaking data on a Nectin-4 ADC.
Brand Name : Nectin-4 ADC
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 08, 2022
Lead Product(s) : Polatuzumab-monomethyl auristatin E
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antibody Drug Conjugate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The poster will highlight preclinical data from Araris’ anti-CD79b antibody-drug conjugate (ADC) program, and the company will also present data on a Nectin-4 ADC. The company’s ADCs were built using Araris’ proprietary peptide linker technology.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : Antibody Drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?